Skip To Main Content
Align Rx on Muck Rack

Align Rx

As seen in: Employee Benefit News, Med Device Online, Life Science Leader, Pharmaceutical Online
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to Align Rx’s profile

Articles by Align Rx

08.27.21 -- Why We Shouldn't Be Categorizing Digital Therapeutics As Drugs

|
By Beckie Fenrick, Align Rx, Dan Hudgins, Mark Robbins
| Pharmaceutical Online Verified
Article | By Dan Hudgins, Ph.D., Anton Paar USA As nanoindentation methods have evolved, so too have the innovative solutions for performing this critical testing, such as the Bioindenter instrument from Anton Paar. Article | By Mark Robbins, Uquifa S.A.U. Executives must take an early and active role in vetting potential partners by using a deeper understanding of the capabilities and characteristics a CDMO should have to successfully bring a product to market.
Open in Who Shared Issue with article?

Why We Shouldn’t Be Categorizing Digital Therapeutics As Drugs

|
By Beckie Fenrick, Align Rx
| Med Device Online
By Beckie Fenrick, AlignRx Digital therapeutics (DTx) have been increasingly popular since smartphones and wearable tech became ubiquitous. The pandemic has set them on a trajectory for massive growth and mainstream adoption. Currently, there is inconsistency in how DTx are handled by payers and health plans, which sometimes treat them as medications. The manufacturer would have a role in this determination. The manufacturer submits the digital therapeutic for FDA review as a device, not as a drug.
Open in Who Shared Issue with article?

Why We Shouldn’t Be Categorizing Digital Therapeutics As Drugs

|
By Beckie Fenrick, Align Rx
| Life Science Leader Verified
By Beckie Fenrick, AlignRx Digital therapeutics (DTx) have been increasingly popular since smartphones and wearable tech became ubiquitous. The pandemic has set them on a trajectory for massive growth and mainstream adoption. Currently, there is inconsistency in how DTx are handled by payers and health plans, which sometimes treat them as medications. The manufacturer would have a role in this determination. The manufacturer submits the digital therapeutic for FDA review as a device, not as a drug.
Open in Who Shared Issue with article?

Why We Shouldn’t Be Categorizing Digital Therapeutics As Drugs

|
By Beckie Fenrick, Align Rx
| Pharmaceutical Online Verified
By Beckie Fenrick, AlignRx Digital therapeutics (DTx) have been increasingly popular since smartphones and wearable tech became ubiquitous. The pandemic has set them on a trajectory for massive growth and mainstream adoption. Currently, there is inconsistency in how DTx are handled by payers and health plans, which sometimes treat them as medications. The manufacturer would have a role in this determination. The manufacturer submits the digital therapeutic for FDA review as a device, not as a drug.
Open in Who Shared Issue with article?
Show More